CPRX News and Press, Catalyst Pharmaceuticals Inc. From 11/10/20

Catalyst Pharmaceuticals, Inc. (CPRX) Q3 2020 Earnings Conference Call November 10, 2020 8:30 AM ET Company Participants Alicia Grande - Chief Financial Officer Patrick McEnany - Chairman & Chief Executive Officer Steven Miller - Chief Operating Officer & Chief Scientific Officer Jeff...

Catalyst Pharmaceuticals (CPRX): Q3 GAAP EPS of $0.41 beats by $0.31.Revenue of $29.32M (-5.1% Y/Y) misses by $2.18M.Cash and equivalents and investments of $127.1M and no funded debt.Shares +1.81% AH.Press Release For further details see: Catalyst Pharmaceuticals EPS beats by $0.31, mi...

- Firdapse ® Third Quarter Net Revenues of $ 29. 2 Million - Company Ends Third Quarter with $127.1 Million in Cash and Investments - U.S. Patent Issued for Firdapse ® and E xpires April 7, 2034 ...

3 Penny Stocks To Buy For Under $4 Are you looking for small cap stocks right now? While many of these could be penny stocks , not all things defined as “small-cap” trade below $5 a share. In fact, the main focus when looking at any “cap stock” is the...

CORAL GABLES, Fla., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurologic...

Catalyst Pharmaceuticals (CPRX) has filed patent infringement litigation in two U.S. district courts against Jacobus Pharmaceuticals and PantherRx Rare LLC, respectively, related to their marketing of Ruzurgi (amifampridine, 10 mg), an unauthorized generic version of Firdapse (amifampridine) ...

CORAL GABLES, Fla., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurologic...

Catalyst Pharmaceuticals has dipped in recent months due to the lack of positive catalysts for the stock. This has brought renewed value to CPRX with Wall Street analysts predicting as much as 145% upside over the long term. Catalyst Pharma has reduced downside risks in comparison...

United States Patent and Trademark Office issued a new U.S. patent to Catalyst Pharmaceuticals (CPRX) for Firdapse (amifampridine), Patent No. 10,793,893, Methods of Administering 3,4-Diaminopyridine; expires on April 7, 2034.“This patent is directed to innovative m...

CORAL GABLES, Fla., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurologic...